X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in amyotrophic lateral sclerosis animal model.
Lead Product(s): Condensate Modifying Drug
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: ALS Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 16, 2024
Details:
Under the partnership, Chemify and Dewpoint will develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry platform against condensate targets of interest in Dewpoint's oncology and neurodegeneration pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Chemify
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 12, 2023
Details:
The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $745.0 million Upfront Cash: Undisclosed
Deal Type: Partnership March 22, 2023
Details:
Dewpoint Therapeutics and Pfizer will collaborate for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $239.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 06, 2021
Details:
Dewpoint Therapeutics works on organelles inside cells called biomolecular condensates, which it believes can be harnessed to treat diseases including cancer and rare genetic disorders. Condensates are membrane-less droplets that help cells perform vital functions.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $77.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2020
Details:
Merck will apply Dewpoint’s proprietary platform for condensate-based drug discovery for the development of a novel mechanism to treat HIV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: $305.0 million
Deal Type: Collaboration July 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
